Company profile: Utility Therapeutics
1.1 - Company Overview
Company description
- Provider of antibiotics focused on combating multi-drug resistant bacterial infections in the US, including PIVYA (pivmecillinam, oral) for UTIs with a unique mode of action addressing resistance, and mecillinam (IV) targeting penicillin binding protein-2 in gram-negative bacteria and stable against β-lactamase hydrolysis, plus a development program working with the FDA to make PIVYA tablets available for uncomplicated UTIs in the US.
Products and services
- PIVYA (pivmecillinam, oral): Clinical-grade oral antibiotic engineered for UTIs, featuring a unique mode of action that addresses resistance issues and supports effective treatment of uncomplicated urinary tract infections
- Development program for PIVYA: FDA-aligned initiative architected to make PIVYA tablets available in the US for treating uncomplicated UTIs, working directly with the FDA
- Mecillinam (IV): Hospital-grade intravenous antibiotic that targets penicillin binding protein-2 in gram-negative bacteria and offers stability against β-lactamase hydrolysis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Utility Therapeutics
Pharmasset
HQ: United States
Website
- Description: Provider of novel oral therapeutics to treat viral infections, with a primary focus on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Clinical-stage pharmaceutical company committed to discovering, developing, and commercializing antiviral drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmasset company profile →
Bluejay Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for infectious diseases, including BJT-778, a fully human IgG1 monoclonal antibody designed to neutralize and facilitate clearance of HDV virions, contributing to a potential functional cure for CHB/CHD, and BJT-628, an oral liver-targeted HBV transcript inhibitor reducing HBsAg. Offers the Bluejay L-TAP platform for liver-targeted oral delivery and runs Phase 1/2a trials in chronic hepatitis B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluejay Therapeutics company profile →
AiCuris
HQ: Germany
Website
- Description: Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCuris company profile →
BioHelix
HQ: United States
Website
- Description: Provider of simple molecular diagnostic tests for the near patient setting, developed to improve the quality of healthcare.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioHelix company profile →
Sunshine Biopharma
HQ: United States
Website
- Description: Provider of research, development, and commercialization of drugs for the treatment of various forms of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunshine Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Utility Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Utility Therapeutics
2.2 - Growth funds investing in similar companies to Utility Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Utility Therapeutics
4.2 - Public trading comparable groups for Utility Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →